Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage

Re, Francesca; Arpinati, Mario; Testoni, Nicoletta; Ricci, Paolo F.; Terragna, Carolina; Preda, Paola; Ruggeri, Deborah; Senese, B; Chirumbolo, Gabriella; Martelli, Valeria; Urbini, Benedetta; Baccarani, Michele; Tura, S; Rondelli, Damiano

doi:10.1016/s0301-472x(01)00768-8

Cited by 39 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phenotypic markers with reported prognostic value, for example, CD34, CD86 and CD14 are shown. 4,5 As described previously, cultured AML-DC are characterized by an increased expression as well as an increased MFI of the most important DC markers CD40, CD54, CD80, CD86, CD83 and HLA-DR as compared to uncultured blasts. 1,3 Cells with the DC phenotype were not detected before culture.…”

mentioning

confidence: 82%

“…Furthermore, the expression of CD86 on AML blasts has been associated with the generation of leukemic DC. 5 It was found that the CD34 þ /CD86 þ subset could be differentiated into leukemic DC in 6 days of culture, especially in CD14 À cases. 5 In our population for both CD86 and CD34 we could not confirm this relation, possibly due to differences in culture periods.…”

mentioning

confidence: 99%

“…Amplifications of the MYC and MLL genes have been previously reported in acute myeloid leukemia (AML), [2][3][4] and of AML1 and MLL in ALL. 3,5 Although amplification of the BCR/ABL fusion gene has been described in cases of chronic myeloid leukemia (CML) treated with imatinib mesylate, seen both as HSRs 6 and dmins, 7 amplification of ABL alone is rare. A six-fold and a 15-fold amplification of the gene have been described in the CML-derived cell line, K562, 8 and in a patient with CML in lymphoid blast crisis, respectively.…”

mentioning

confidence: 99%

“…In order to confirm that the amplified region included the ABL gene, three PAC probes mapping 5 0 to 3 0 from intron 1 (dJ1132H12, dJ913J14 and dJ888H1, Dr Rocchi, Bari, Italy) and two mapping to downstream exons (including exon 11) (dJ835J22 and dJ1146L15, Dr Rocchi, Bari, Italy) were hybridized individually onto interphase and metaphase cells from the nine samples, as previously described. 5 In patient 4273, the amplified ABL signals were counted automatically using a Cytovision SPOT AX system (Applied Imaging International Ltd, UK).…”

mentioning

confidence: 99%

See 3 more Smart Citations

TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells

et al. 2004

View full text Add to dashboard Cite

TNF-a receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells Leukemia (2004) the unique ability to differentiate into leukemic DC, thereby conserving their intrinsic leukemia antigen repertoire and obtaining full potential of antigen presentation. We have shown that DC generated from acute myeloid leukemic (AML) blasts are able to initiate autologous cytotoxic T-cell responses, and thus hold promise for vaccination purposes in a minimal residual disease (MRD) status. 1 In a recently performed phase-I study on CML-DC vaccination in advanced stage chronic myeloid leukemia (CML), we were able to detect strong DTH-responses representing autologous CML-specific T-cell responses. 2 The presence of various cytokines such as GM-CSF, SCF, Flt3-L, TNF-a, IL-3 and IL-4 induces differentiation into AML-DC in approximately 2 weeks, also under clinical grade serum-free The PIG3 polymorphic promoter shows LOH in de novo AML. Electropherograms obtained with labeled PCR products containing the PIG3 microsatellite (TGYCC)n. Top: sample obtained at diagnosis displayed a loss of the 17 repeats allelle (arrow). Bottom: sample obtained at remission. 1149Leukemia conditions. 1, 3 We showed previously that it is also possible to generate AML-DC in a 2-day culture period by the incubation with calcium ionophores (CI), thereby bypassing receptor mediated signalling. 1 AML-DC cultured by CI displayed, both phenotypically and functionally, a more mature state than those cultured with a combination of cytokines. However, CI-cultured cells were found to be less viable. 1 Consequently, the CI-based method can only be used if high amounts of AML blasts are available. The common use of the cytokine-based method to develop AML-DC is accompanied by a variable DC differentiation inducibility, irrespective of French-American-British (FAB) classification. For these reasons, we examined the possibility to select a culture method in advance that will result in the most optimal generation of AML-DC for each individual patient. In this study we investigated whether the cytokine receptor profile of AML blasts is predictive for the ability to differentiate into AML-DC. After informed consent, peripheral blood and bone marrow mononuclear cells of AML patients were collected. A total of 33 patients (21 female, 12 male) were included with a median age of 60 years (range: 22-88), with the following FAB classifications: M0 (2), M1 (5), M2 (5), M4 (8), M5 (10), RAEB-t (1), unclassified (2). AML cells were cultured as published previously. 1,3 Briefly, fresh or thawed mononuclear cells were cultured in either RPMI-1640; 20% fetal calf serum; 100 U/ml penicillin and 100 mg/ml streptomycin (n ¼ 6) or Stem Spant SFEM serum-free medium (n ¼ 27); 100 U/ml penicillin and 100 mg/ml streptomycin. Differentiation towards DC was induced by the addition of a combination of cytokines (n ¼ 33): GM-CSF, TNF-a, IL-3, SCF, Flt3-L and IL-4 or CI A23187 and IL-4 (n ¼ 28). 1,3 IL-4 was added to the CI culture to prevent the...

show abstract

mentioning

confidence: 82%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells

et al. 2004

View full text Add to dashboard Cite

show abstract

“…119 Similar findings have since been reported by other investigators. [120][121][122][123][124][125][126][127][128][129][130][131][132] The high number of efficient co-stimulatory, adhesion and MHC molecules present on the membrane of these leukemic DCs could allow recruitment and activation of the rare specific anti-tumoral T cells that are supposed to belong to the naive lymphocyte pool. Moreover, to overcome the absence of identified leukemia-associated antigens, in the case of leukemic DCs, tumor cells themselves are used as immunogens.…”

Section: Potential Therapy With Leukemia-derived Dcsmentioning

confidence: 99%

Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts

2002

View full text Add to dashboard Cite

Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia

Jin

Zhang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background CD300s are a group of proteins playing vital roles in immune responses. However, much is yet to be elucidated regarding the expression patterns and clinical significances of CD300s in cancers. Methods In this study, we comprehensively investigated CD300s in a pan‐cancer manner using multi‐omic data from The Cancer Genome Atlas. We also studied the relationship between CD300s and the immune landscape of AML. Results We found that CD300A ‐ CD300LF were generally overexpressed in tumors (especially AML), whereas CD300LG was more often downregulated. In AML, transactivation of CD300A was not mediated by genetic alterations but by histone modification. Survival analyses revealed that high CD300A ‐ CD300LF expression predicted poor outcome in AML patients; the prognostic value of CD300A was validated in seven independent datasets and a meta dataset including 1115 AML patients. Furthermore, we demonstrated that CD300A expression could add prognostic value in refining existing risk models in AML. Importantly, CD300A ‐ CD300LF expression was closely associated with T‐cell dysfunction score and could predict response to AML immunotherapy. Also, CD300A was found to be positively associated with HLA genes and critical immune checkpoints in AML, such as VISTA , CD86 , CD200R1 , Tim‐3 , and the LILRB family genes. Conclusions Our study demonstrated CD300s as potential prognostic biomarker and an ideal immunotherapy target in AML, which warrants future functional and clinical studies.

show abstract

Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage

Cited by 39 publications

References 29 publications

TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells

TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells

Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts

Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia

Contact Info

Product

Resources

About